Collectively, these in vitro and in vivo findings establish SMC4 as a critical facilitator of glioma metastasis by potently activating the TGF-β/SMAD signaling axis, highlighting its therapeutic potential as a target for inhibiting metastatic progression in glioma. Here, SMC4 is linked to glioma.